Sentinel lymph node biopsy was used in patients with thin melanomas who did not have high-risk features and who had a very low risk for sentinel lymph node positivity prior to guidelines recommending against its use in this setting, according to observational study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
MRV Research
Erlotinib, bevacizumab yield negligible outcome in metastatic melanoma
The combination of erlotinib and bevacizumab was tolerable yet displayed minimal clinical activity in patients with metastatic melanoma, according to phase 2 study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting in New York.
FDA grants orphan drug designation to Samcyprone for malignant stage IIb to IV melanoma
RXi Pharmaceuticals announced it has received orphan drug designation from the FDA for Samcyprone, its clinical candidate for treating malignant melanoma stage IIb to IV.
FDA Grants AstraZeneca’s Selumetinib Orphan Drug Status for Treatment of Uveal Melanoma –Update
AstraZeneca PLC’s (AZN.LN) selumetinib drug has been granted a special status by the U.S. Food and Drug Administration for treatment of Uveal melanoma, a rare eye disease.